Drugs / Fluzone Trivalent
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06664151 | Nov 2024 → Aug 2026 overdue | skin squamous cell carcinoma | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzone Trivalent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06664151 ↗ |
| Modality | Vaccine | “Inactivated influenza vaccine” NCT06664151 ↗ |
| Route | Other | “via intratumoral (into a tumor) injection per protocol.” NCT06664151 ↗ |